The U.S. Food and Drug Administration said on September 4, 2026 that it is taking regulatory action to prevent a potential supply gap in neonatal starter parenteral nutrition, the IV-delivered nutrition that sustains premature and critically ill newborns who cannot eat by mouth or feeding tube, according to the official release. The agency said the step follows warnings from children's hospitals about discontinued products tied to two outsourcing facilities that are permanently closing.
Key takeaways
- The FDA announced on September 4, 2026 that it is acting to prevent a potential supply gap in neonatal starter parenteral nutrition, the IV-delivered nutrition used for premature and critically ill newborns.
- The gap was triggered by the permanent shutdown of two outsourcing facilities that made standardized neonatal starter PN products, which children's hospitals flagged to the agency.
- The FDA issued an immediately-in-effect guidance, 'Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates,' setting temporary regulatory and enforcement priorities for compounders.
- The guidance applies to state-licensed pharmacies, federal facilities and outsourcing facilities compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, while the FDA says it will keep monitoring supply and consider further action.
Why Hospitals Raised the Alarm
The FDA said it became aware of the potential supply problem after children's hospitals raised concerns about continued access to neonatal starter parenteral nutrition. According to the agency, those concerns stemmed from the discontinuation of certain standardized neonatal starter PN products that had been made by two outsourcing facilities, both of which are permanently shutting down.
Starter parenteral nutrition is used specifically for newborns who need nutrients delivered intravenously soon after birth because they cannot yet tolerate oral or tube feeding. The FDA's release underscores that this population, premature and critically ill infants, is especially vulnerable to any interruption in a standardized, ready-to-use nutrition supply.
What the New FDA Guidance Does
In response, the FDA said it assessed the situation and identified ways to help prevent a disruption in supply. The centerpiece of that effort is an immediately-in-effect guidance document titled 'Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates,' which lays out the agency's temporary regulatory and enforcement priorities for certain compounded starter PN drug products.
The guidance describes regulatory and enforcement priorities for state-licensed pharmacies, federal facilities and outsourcing facilities that compound specified parenteral drugs under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Those two sections of federal law set the conditions under which pharmacies and outsourcing facilities may legally compound medications outside the FDA's standard new-drug approval process, typically to meet patient-specific needs or address shortages.
"The FDA is committed to deploying every regulatory tool available to prevent critical supply chain gaps from threatening patient care," said Acting FDA Commissioner Kyle Diamantas, J.D., in the release. "We are working closely with healthcare providers and industry partners to help ensure that vulnerable populations continue to have access to the care they need."
The Numbers Behind the Announcement
The FDA's release is a policy and guidance announcement rather than a statistical report, so it does not include quantitative supply figures, production volumes or shortage percentages. The table below reflects the specific figures and dates the agency did disclose.
| Measure | Latest figure | Previous/comparison figure | Change |
|---|---|---|---|
| Outsourcing facilities discontinuing standardized neonatal starter PN products | Two facilities | Not stated | Not stated |
| Guidance effective date | September 4, 2026 (immediately in effect) | Not stated | Not stated |
| Affected patient population | Premature and critically ill newborns unable to feed orally or by tube | Not stated | Not stated |
How Compounding and FDA Oversight Normally Work
Parenteral nutrition is typically manufactured or compounded in standardized formulations so hospitals can keep a ready supply on hand for newborns who need it urgently, often within hours of birth. Outsourcing facilities registered under section 503B of the Federal Food, Drug, and Cosmetic Act are permitted to compound such drugs in larger batches without individual patient prescriptions, subject to FDA oversight, while state-licensed pharmacies compounding under section 503A generally prepare products for specific patients.
When a 503B outsourcing facility shuts down, hospitals can lose access to a standardized product line all at once, which is why the FDA said it is using its guidance authority to temporarily adjust enforcement priorities rather than waiting for a new manufacturer to come online. The FDA, part of the U.S. Department of Health and Human Services, is responsible for assuring the safety and effectiveness of human drugs, biological products and medical devices, and routinely issues such temporary guidances during shortages to give hospitals and compounders a clear, immediate path while longer-term manufacturing solutions are arranged.
Michael Davis, M.D., Ph.D., Acting Center Director of the FDA's Center for Drug Evaluation and Research, said in the release that "starter parenteral nutrition is especially important for premature and critically ill newborns who need nutrition soon after birth," and that "these temporary policies are intended to help hospitals maintain access to this life-saving nutrition during this transition."
What Happens Next
The FDA said it will continue to monitor current and expected supply needs and assess whether additional action is needed as the situation develops. The agency did not specify a timeline for when the temporary guidance might be revised, replaced, or allowed to expire, nor did it name the two outsourcing facilities that are closing.
The release frames the guidance as a bridge measure meant to keep hospitals supplied while what the agency calls "longer-term solutions" are identified, without detailing what those longer-term solutions might involve.
Frequently asked questions
What is neonatal starter parenteral nutrition used for?
It is a nutrition product delivered intravenously to premature and critically ill newborns who cannot yet receive nutrition by mouth or through a feeding tube, according to the FDA. It provides essential nutrients soon after birth during a critical window for these infants.
Why is there a potential supply gap?
The FDA said children's hospitals raised concerns after certain standardized neonatal starter PN products were discontinued because two outsourcing facilities that made them are permanently shutting down. The agency did not name the facilities or specify when the closures took effect.
Who does the new FDA guidance apply to?
The guidance sets temporary regulatory and enforcement priorities for state-licensed pharmacies, federal facilities and outsourcing facilities that compound specified parenteral drugs under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. It is intended to help these compounders continue supplying hospitals with starter PN products for neonates.
Is the guidance permanent?
No, the FDA describes it as a temporary policy meant to bridge the gap while longer-term solutions are identified. The agency said it will keep monitoring supply needs and could take additional action as the situation develops.